Aspirin: A history, a love story

Consultant Pharmacist

Volumn 27, Issue 5, 2012, Pages 322-329

  Wick, Jeannette Y ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NONE

Author keywords

Acetylsalicylic acid; Aspirin; Cardiovascular disease

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARACETAMOL; QUININE; ROFECOXIB; SALICIN; SALICYLIC ACID; SALIGENIN;

ANALGESIA; ANGIONEUROTIC EDEMA; BLEEDING; BRONCHOSPASM; DRUG INDUSTRY; DRUG MECHANISM; ENZYME INHIBITION; FEVER; GASTRODUODENAL ULCER; HEADACHE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LOW BACK PAIN; NEOPLASM; NEURALGIA; NEURITIS; PAIN; PHARMACIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; REYE SYNDROME; RHEUMATIC DISEASE; RHINITIS; SHOCK; STROKE; TINNITUS; TOOTH PAIN; URTICARIA; VOMITING;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BENZYL ALCOHOLS; CARDIOVASCULAR DISEASES; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; GLUCOSIDES; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS; SALIX; SEX CHARACTERISTICS;

EID: 84861646846     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2012.322     Document Type: Review

References (46)

1. Szczeklik A. The history of aspirin: the discoveries that changed contemporary medicine. In Arber W, ed. Paths of Discovery. Rome, Italy: Vatican Press; 2006:176-84.
2. Elwood PC. Aspirin: past, present and future. Clin Med 2001;1:132-7. (Pubitemid 32410180)
3. Boullata JI, McDonnell PJ, Oliva CD. Anaphylactic reaction to a dietary supplement containing willow bark. Ann Pharmacother 2003;37:832-5. (Pubitemid 36618372)
4. Auyang SY. From experience to design - the science behind aspirin. Creating Technology: Engineering and Biomedicine. Available at http://www.creating technology.org/biomed/aspirin. pdf. Accessed September 20, 2011.
5. Clauson KA, Santamarina ML, Buettner CM et al. Evaluation of presence of aspirin-related warnings with willow bark. Ann Pharmacother 2005;39:1234-7. (Pubitemid 40943175)
6. Vlachojannis J, Magora F, Chrubasik S. Willow species and aspirin: different mechanism of actions. Phytother Res 2011 Jan 12. doi: 10.1002/ptr.3386. [Epub ahead of print]
7. Tiliakos AM, Conn DL. Aspirin: antiinflammatory drug of choice in 2011? J Rheumatol 2011;38:185-7.
8. Pierpoint WS. Samuel James (c1763-1831) of Hoddesdon and the medicinal use of willow bark. J Med Biogr 2007;15:23-30.
9. Jeffreys D. Aspirin: The Remarkable Story of a Wonder Drug. London, UK: Bloomsbury; 2004:352 pp.
10. Friend DG. Aspirin: the unique drug. Arch Surg 1974;108:765-9.
11. Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal 2011;3:337-44.
12. Bowden ME, Crow AB, Sullivan T. Pharmaceutical Achievers. Philadelphia, PA: Chemical Heritage Press; 2003.
13. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8. (Pubitemid 37329821)
14. D'Acquisto F, Ianaro A. From willow bark to peptides: the ever-widening spectrum of NF-kappaB inhibitors. Curr Opin Pharmacol 2006;6:387-92.
15. Douthwaite AH, Linott SAM. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 1938;2:1222-5.
16. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84. (Pubitemid 23064991)
17. Aw TJ, Haas SJ, Liew D et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6. (Pubitemid 40344379)
18. Schneider V, Lévesque LE, Zhang B et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006;164:881-9. (Pubitemid 44627273)
19. Sandler DP, Smith JC, Weinberg CR et al. Analgesic use and chronic renal disease. N Engl J Med 1989;320:1238-43. (Pubitemid 19128119)
20. Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991;151:1309-13.
21. Kowalski ML, Makowska JS, Blanca M et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - Classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011;66:818-29.
22. Quennery S, Cornu O, Sneyers B et al. Added value of pharmacist-acquired drug histories in an orthopaedic ward. Acta Clin Belg 2011;66:196-9.
23. Shelley WB. Birch pollen and aspirin psoriasis. A study in salicylate hypersensitivity. JAMA 1964;189:985-8.
24. Altman L. New uses for aspirin actually observed by California doctor 40 years ago:[1-DOT Edition] Baltimore, MD: The Sun; September 1, 1991:11.
25. Miner J, Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J 2007;34:179-86. (Pubitemid 47066594)
26. Craven LL. Coronary thrombosis can be prevented. J Insur Med 1950;5:47-8.
27. Smith SC Jr, Blair SN, Bonow RO et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581-3. (Pubitemid 33033046)
28. Patrono C, Bachmann F, Baigent C et al European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004;25:166-81. (Pubitemid 38112156)
29. Baigent C, Blackwell L, Collins R et al; Antithrombotic Trialists'(ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
30. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev 2002;(4):CD003242.
31. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
32. Juul-Möller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.
33. Levin RI. The puzzle of aspirin and sex. N Engl J Med 2005;352:1366-8. (Pubitemid 40411503)
34. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
35. Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
36. Jankowski J, Hunt R. Cyclooxygenase-2 inhibitors in colorectal cancer prevention; better the devil you know. Cancer Epidemiol Biomarkers Prevent 2009;17:1858-61.
37. U.S. Preventive Services Task Force. Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer, 2007. Available at http://www. uspreventiveservicestaskforce.org/uspstf/uspsasco.htm. Accessed December 3, 2011.
38. Feher A, Pusch G, Harang G et al. Aspirin resistance in cerebrovascular patients. Int J Cardiol 2011;152:111-2.
39. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
40. Feher G, Feher A, Pusch G et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol 2010;2:171-86.
41. Gokturk HS, Demir M, Unler GK et al. Does long-term aspirin use have any effect on Helicobacter pylori eradication? Am J Med Sci 2011;342:15-9.
42. Gresele P, Migliacci R, Procacci A et al. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 2007;97:444-50. (Pubitemid 46437807)
43. Gresele P, Marzotti S, Guglielmini G et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010;33:1262-8.
44. Derhaschnig U, Schweeger-Exeli I, Marsik C et al. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. Platelets 2010;21:320-8.
45. Hayreh SS, Podhajsky PA, Zimmerman MB. Central and hemicentral retinal vein occlusion: role of anti-platelet aggregation agents and anticoagulants. Ophthalmology 2011;118:1603-11.
46. Kiernan DF, Hariprasad SM, Rusu IM et al. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina 2010;30:1573-8.